@article{a0e847af4d7a4c50af774e4fa00c655e,
title = "Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project: The Lancet Haematology",
abstract = "Background: Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a unique clinicopathological entity, typically associated with poor survival outcomes. Most published data have come from east Asian study groups, with little information available from international cohorts. The effects of treatment advances on routine clinical practice across continental territories has not been clear. We aimed to improve understanding of the clinical characteristics and outcomes of patients with ENKTL. Methods: We did a substudy of patients with ENKTL from the T-cell Project, a global prospective cohort study. The T-cell Project registered consecutively diagnosed adults (>18 years) with newly diagnosed, untreated mature T-cell or NK lymphomas (WHO 2001 or 2008 classifications) from 74 centres in 13 countries (in Asia, Europe, North America, and South America). In total, 1695 patients with mature T-cell or NK lymphomas were enrolled between Oct 12, 2006 and Feb 28, 2018 in the T-cell Project. The first patient with ENKTL was enrolled on Feb 15, 2007, and the last on May 26, 2017. Data on baseline characteristics, first-line treatment, treatment response, and survival outcomes were recorded in a central database (locked March 30, 2019). The primary outcome was 5-year overall survival. The T-cell Project is registered on ClinicalTrials.gov, NCT01142674. Findings: 166 patients were diagnosed with ENKTL, comprising 11% of 1553 eligible registered cases and distributed across 40 participating centres in four continents. At a median follow-up of 44 months (IQR 20–61), overall survival at 5 years was 54% (95% CI 44–63) in patients with nasal disease (n=98) and 34% (27–46) in patients with extranasal disease (n=68). Interpretation: To our knowledge, this study presents the largest international cohort of patients with ENKTL. We describe a clinically significant improvement in the survival of patients with ENKTL treated in routine clinical practice over the past decade, likely to be attributable to the increasing use of treatment protocols specific for ENKTL. Funding: The Fondazione Cassa di Risparmio di Modena, the Associazione Angela Serra per la Ricerca sul Cancro, the Fondazione Italiana Linfomi, Allos Therapeutics, Spectrum Pharmaceuticals, Associazione Italiana per la Ricerca sul Cancro, and the National Cancer Institute at the National Institutes of Health. {\textcopyright} 2020 Elsevier Ltd",
keywords = "anthracycline, asparaginase, brentuximab vedotin, cisplatin, dexamethasone, etoposide, gemcitabine, ifosfamide, lactate dehydrogenase, methotrexate, platinum, antineoplastic agent, adult, aged, Article, cancer immunotherapy, cancer prognosis, cancer research, cancer survival, cause of death, clinical outcome, clinical trial, cohort analysis, controlled study, death, disease free survival, female, follow up, human, International Prognostic Index, major clinical study, male, multicenter study, NK T cell lymphoma, outcome assessment, overall survival, priority journal, progression free survival, prospective study, recurrence free survival, retrospective study, survival analysis, treatment outcome, treatment response, adolescent, factual database, middle aged, mortality, multimodality cancer therapy, very elderly, young adult, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cohort Studies, Combined Modality Therapy, Databases, Factual, Female, Humans, Lymphoma, Extranodal NK-T-Cell, Male, Middle Aged, Progression-Free Survival, Prospective Studies, Survival Analysis, Treatment Outcome, Young Adult",
author = "C.P. Fox and M. Civallero and Y.-H. Ko and M. Manni and T. Skrypets and S. Pileri and S.J. Kim and M.E. Cabrera and A.R. Shustov and C.S. Chiattone and S.M. Horwitz and I. Dlouhy and M. Spina and F. Hitz and S. Montoto and A. Nagler and V. Martinez and {De Souza}, C.A. and R. Fernandez-Alvarez and V. Ballova and R. Gab{\'u}s and G. Inghirami and M. Federico and W.S. Kim",
note = "Cited By :14 Export Date: 3 March 2021 Correspondence Address: Kim, W.S.; Division of Hematology-Oncology, South Korea; email: wskimsmc@skku.edu Chemicals/CAS: asparaginase, 9015-68-3, 1349719-22-7; brentuximab vedotin, 914088-09-8; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; dexamethasone, 50-02-2; etoposide, 33419-42-0, 433304-61-1; gemcitabine, 103882-84-4; ifosfamide, 3778-73-2; lactate dehydrogenase, 9001-60-9; lactate dehydrogenase A; methotrexate, 15475-56-6, 59-05-2, 7413-34-5; platinum, 7440-06-4 Funding details: National Institutes of Health, NIH, CCSG P30 CA008748 Funding details: Spectrum Pharmaceuticals Funding details: Fondazione Cassa di Risparmio di Modena Funding details: Allos Therapeutics Funding details: Associazione Angela Serra per la Ricerca sul Cancro Funding details: Associazione Italiana per la Ricerca sul Cancro, AIRC, 10007, 20198 Funding text 1: For their support of this study, we are thankful to the Fondazione Cassa di Risparmio di Modena (Modena, Italy), the Associazione Angela Serra per la Ricerca sul Cancro (Modena, Italy), the Fondazione Italiana Linfomi (Alessandria, Italy), Allos Therapeutics, Spectrum Pharmaceuticals, Associazione Italiana per la Ricerca sul Cancro, the US National Cancer Institute at the National Institutes of Health (Bethesda, MD, USA; grant number CCSG P30 CA008748 to SMH), and the Italian Association for Cancer Research (Milan, Italy; grant numbers 10007 and 20198 to SP). References: Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, , Revised 4th edn. International Agency for Research on Cancer Lyon; Yamaguchi, M., Suzuki, R., Oguchi, M., Advances in the treatment of extranodal NK/T-cell lymphoma, nasal type (2018) Blood, 131, pp. 2528-2540; Haverkos, B.M., Pan, Z., Gru, A.A., Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases (2016) Curr Hematol Malig Rep, 11, pp. 514-527; Gill, H., Liang, R.H.S., Tse, E., Extranodal natural-killer/t-cell lymphoma, nasal type (2010) Adv Hematol, 2010; Au, W.Y., Weisenburger, D.D., Intragumtornchai, T., Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project (2009) Blood, 113, pp. 3931-3937; Kim, B.S., Kim, T.-Y., Kim, C.W., Therapeutic outcome of extranodal NK/T-cell lymphoma initially treated with chemotherapy—result of chemotherapy in NK/T-cell lymphoma (2003) Acta Oncol, 42, pp. 779-783; Sakata, K., Fuwa, N., Kodaira, T., Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification (2006) Radiother Oncol, 79, pp. 179-184; Li, Y.-X., Yao, B., Jin, J., Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma (2006) J Clin Oncol, 24, pp. 181-189; Lee, J., Suh, C., Park, Y.H., Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study (2006) J Clin Oncol, 24, pp. 612-618; Liang, R., Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type (2009) Br J Haematol, 147, pp. 13-21; Vose, J., Armitage, J., Weisenburger, D., International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes (2008) J Clin Oncol, 26, pp. 4124-4130; Yamaguchi, M., Tobinai, K., Oguchi, M., Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211 (2009) J Clin Oncol, 27, pp. 5594-5600; Jaccard, A., Gachard, N., Marin, B., Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study (2011) Blood, 117, pp. 1834-1839; Kim, S.J., Kim, K., Kim, B.S., Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study (2009) J Clin Oncol, 27, pp. 6027-6032; Yamaguchi, M., Kwong, Y.-L., Kim, W.S., Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study (2011) J Clin Oncol, 29, pp. 4410-4416; Kim, S.J., Park, S., Kang, E.S., Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients (2015) Ann Hematol, 94, pp. 71-78; Cheson, B.D., Pfistner, B., Juweid, M.E., Revised response criteria for malignant lymphoma (2007) J Clin Oncol, 25, pp. 579-586; Kim, S.J., Yoon, D.H., Jaccard, A., A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis (2016) Lancet Oncol, 17, pp. 389-400; Gooley, T.A., Leisenring, W., Crowley, J., Storer, B.E., Estimation of failure probabilities in the presence of competing risks: new representations of old estimators (1999) Stat Med, 18, pp. 695-706; Yamaguchi, M., Suzuki, R., Oguchi, M., Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma diagnosed between 2000 and 2013: a cooperative study in Japan (2017) J Clin Oncol, 35, pp. 32-39; Lai, J., Zhu, Y.Y., Ruan, M., Chen, L., Zhang, Q.Y., Local irradiation sensitized tumors to adoptive T cell therapy via enhancing the cross-priming, homing, and cytotoxicity of antigen-specific CD8 T cells (2019) Front Immunol, 10; Yamaguchi, M., Suzuki, R., Miyazaki, K., Improved prognosis of extranodal NK/T cell lymphoma, nasal type of nasal origin but not extranasal origin (2019) Ann Hematol, 98, pp. 1647-1655; Cho, J., Kim, S.J., Park, S., Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma (2018) Ann Hematol, 97, pp. 1427-1436; Chan, T.S.Y., Li, J., Loong, F., Khong, P.-L., Tse, E., Kwong, Y.-L., PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-asparaginase: efficacy and safety (2018) Ann Hematol, 97, pp. 193-196; Reck, M., Rodr{\'i}guez-Abreu, D., Robinson, A.G., Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer (2016) N Engl J Med, 375, pp. 1823-1833",
year = "2020",
doi = "10.1016/S2352-3026(19)30283-2",
language = "English",
volume = "7",
pages = "e284--e294",
journal = "Lancet Haematol.",
issn = "2352-3026",
publisher = "Elsevier Ltd",
number = "4",
}